Literature DB >> 1917165

Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro.

T Licht1, H H Fiebig, K J Bross, F Herrmann, D P Berger, R Shoemaker, R Mertelsmann.   

Abstract

Induction of P-glycoprotein-related multi-drug-resistance (MDR) has been shown in normal and malignant tissues to result from environmental stresses such as heat shock, exposure to carcinogens or X-ray irradiation. To identify conditions under which MDR is enhanced during anti-neoplastic chemotherapy, a cell line showing low-level intrinsic MDR was investigated. In the pleural mesothelioma cell line, PXF1118, less than 1% of cells expressed P-glycoprotein (P-gp), as shown by immunocytochemical staining with monoclonal antibody (MAb) MRK16. Exposure of PXF1118 to vincristine, vindesine, vinblastine or doxorubicin for 2-3 weeks led to an increase in the MDR cell fraction of up to 15-28% during 2 to 3 weeks. For doxorubicin and vindesine, dose-dependence was observed: drug concentrations not capable of eliciting cytotoxicity failed to induce significant P-gp expression. Nutrient starvation in aging medium, exposure to activated cyclophosphamide (even at high concentrations) or cisplatin caused only negligible MDR induction. After exposure to vindesine for 6 weeks, tumor colonies exhibited highly enhanced resistance to Vinca alkaloids, doxorubicin, etoposide and dacarbacine, whereas their sensitivity to mitomycin, activated cyclophosphamide or cisplatin remained unchanged. As determined by [3H]-thymidine uptake and proliferation antigen expression, induction of MDR phenotype was observed at minimal proliferative activity with no change in cell count during exposure to anti-cancer drugs, thus suggesting that the drug treatments changed the phenotype of the cells rather than selecting for a resistant sub-population. In addition, changes in cell differentiation were observed during MDR induction. Induction of P-gp during exposure to anti-cancer drugs thus provides a model for MDR development during initially successful chemotherapy. of P-gp during exposure to anti-cancer drugs thus provides

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1917165     DOI: 10.1002/ijc.2910490427

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

Review 1.  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Authors:  J W Upham; M J Garlepp; A W Musk; B W Robinson
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

2.  Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85.

Authors:  Elena V Batrakova; David L Kelly; Shu Li; Yili Li; Zhihui Yang; Li Xiao; Daria Y Alakhova; Simon Sherman; Valery Yu Alakhov; Alexander V Kabanov
Journal:  Mol Pharm       Date:  2006 Mar-Apr       Impact factor: 4.939

3.  P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine.

Authors:  Attila Zalatnai
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

4.  Odyssey of a cancer nanoparticle: from injection site to site of action.

Authors:  Joseph W Nichols; You Han Bae
Journal:  Nano Today       Date:  2012-12-01       Impact factor: 20.722

Review 5.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

6.  Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R).

Authors:  Milica Pesić; Tijana Andjelković; Jasna Banković; Ivanka D Marković; Ljubisa Rakić; Sabera Ruzdijić
Journal:  Invest New Drugs       Date:  2008-05-21       Impact factor: 3.850

7.  Expression of the proliferation-associated Ki-67 antigen of transferrin receptors and of DNA polymerase alpha in human tumour lines: implications for in vitro chemoresistance.

Authors:  T Licht; K J Bross; H H Fiebig; K Schötta; D P Berger; C Dreher; G W Löhr; F Herrmann
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.

Authors:  V Gekeler; J Beck; A Noller; A Wilisch; G Frese; M Neumann; R Handgretinger; G Ehninger; H Probst; D Niethammer
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

9.  Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent.

Authors:  U Stein; W Walther; R H Shoemaker
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

10.  Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant.

Authors:  Amit K Sharma; Li Zhang; Shu Li; David L Kelly; Valery Yu Alakhov; Elena V Batrakova; Alexander V Kabanov
Journal:  J Control Release       Date:  2008-07-30       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.